Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of oral TAK-385 for pain symptoms associated with uterine fibroids
jRCT2080223073Phase 3
- Sponsor
- Takeda
- Start
- Jan 2016
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Fibromyoma (LM) comparing TAK-385 40 mg with Placebo (2 arms).
02
Drugs
tissue-plasminogen activator
03
Conditions
Fibromyoma (LM)
Beyond the preview
Go deeper on jRCT2080223073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223073.